Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 9;56(12):677.
doi: 10.3390/medicina56120677.

Procoagulant Disorders in Patients with Newly Diagnosed Pancreatic Adenocarcinoma

Renata Talar-Wojnarowska  1 , Małgorzata Woźniak  1 , Anna Borkowska  2 , Katarzyna Cypryk  2 , Marek Olakowski  3 , Ewa Małecka-Panas  1
Affiliations

Procoagulant Disorders in Patients with Newly Diagnosed Pancreatic Adenocarcinoma

Renata Talar-Wojnarowska et al. Medicina (Kaunas). .

Abstract

Background and objectives: Cancer coagulopathy is thought to be partially due to the up-regulation of tissue factor (TF), thrombin-antithrombin complex (TAT) and soluble P-selectin (sP-selectin). The purpose of this study was to evaluate the clinical significance of TF, TAT and sP-selectin in patients with pancreatic cancer. Materials and methods: The study included 93 subjects: 73 newly diagnosed patients with pancreatic adenocarcinoma (42 with stage I-III and 31 with metastatic cancer (stage IV)) and a control group of 20 healthy subjects. Analyzed patients were hospitalized in the Department of Digestive Tract Diseases, Medical University of Lodz or in the Department of Digestive Tract Surgery, Silesian University, Katowice, Poland. All laboratory parameters were measured using ELISA procedures. Results: TF plasma levels were detectable in all patients and were significantly higher in metastatic cancer compared to stage I-III patients and the control group (p < 0.05). In patients with pancreatic adenocarcinoma, the median levels of TAT were also elevated compared to the control group. Moreover, patients with metastases had significantly higher TAT concentration compared to the I-III cancer group. On the other hand, only the metastatic patients group showed significantly higher plasma sP-selectin levels compared to the controls (p = 0.009), whereas there was no difference between localized and metastatic cancer patients. Conclusions: The coagulation disorders are present in the majority of patients with pancreatic adenocarcinoma already at the diagnosis stage and reflect cancer progression and spread.

Keywords: coagulopathy; pancreatic adenocarcinoma; sP-selectin; thrombin-antithrombin complex; tissue factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Comparison of tissue factor (TF) levels in patients with different stage of pancreatic adenocarcinoma (PA) and the control group.
Figure 2
Figure 2
Positive correlation between tissue factor (TF) plasma levels and C-reactive protein (CRP) in all patients with pancreatic adenocarcinoma.
Figure 3
Figure 3
Comparison of thrombin-antithrombin complex (TAT) levels in patients with different stages of pancreatic adenocarcinoma (PA) and the control group.
Figure 4
Figure 4
Positive correlation between trombin-antithrombin complex (TAT) plasma levels and C-reactive protein (CRP) in all patients with pancreatic adenocarcinoma.
Figure 5
Figure 5
Comparison of sP-selectin levels in patients with different stages of pancreatic adenocarcinoma (PA) and the control group.
See this image and copyright information in PMC

References

    1. Emmerich J. Epidemiology of venous thrombosis. Bull. Acad. Natl. Med. 2003;187:19–32. - PubMed
    1. Falanga A., Russo L., Milesi V. The coagulopathy of cancer. Curr. Opin. Hematol. 2014;21:423–429. doi: 10.1097/MOH.0000000000000072. - DOI - PubMed
    1. Ishigaki K., Nakai Y., Isayama H., Saito K., Hamada T., Takahara N., Mizuno S., Mohri D., Kogure H., Matsubara S., et al. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Pancreas. 2017;46:1069–1075. doi: 10.1097/MPA.0000000000000889. - DOI - PubMed
    1. Wysocka O., Kulbacka J., Saczko J. Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Gastroenterol. Rev. 2016;11:155–162. doi: 10.5114/pg.2016.61438. - DOI - PMC - PubMed
    1. Menapace L.A., Peterson D.R., Berry A., Sousou T., Khorana A.A. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb. Haemost. 2011;106:371–378. doi: 10.1160/TH10-12-0789. - DOI - PubMed